Literature DB >> 26729327

Mood Disorders in Uncontrolled Hypertension Despite Multiple Anti-Hypertensive Medications: Searching for a Link.

Alberto Mazza1,2, Roberta Ravenni3, Michela Armigliato4, Ciro Rossetti4, Laura Schiavon4, Fulvio Fiorini5, Gianluca Rigatelli6, Emilio Ramazzina4, Edoardo Casiglia7.   

Abstract

INTRODUCTION: Resistant hypertension is a clinical condition in which blood pressure (BP) control is not achieved under a pharmacological therapy including a diuretic and at least two additional antihypertensive drug classes. AIM: To discuss an unusual presentation of uncontrolled hypertension despite multiple anti-hypertensive medications. METHODS AND
RESULTS: A 46-year-old woman presented with resistant hypertension (HT) and with a long history of polydipsia, polyuria, weight loss and psychiatric symptoms (sudden onset of personality disorder with free anxiety, negativism and asthenia) unsuccessfully treated with antidepressant drugs. Tests for secondary HT showed a marked increase of serum renin and aldosterone both in clinostatic (342 pg/ml and 907 pmol/l, respectively) and orthostatic posture (351 pg/ml and 2845 pmol/l, respectively), hypokalemia (2.9 mmol/l) and macroalbuminuria (431 mg/day). Diagnostic examinations also revealed a focal stenosis of approximately 70 % of the proximal right renal artery with post-stenotic dilation. After percutaneous balloon angioplasty and stent implantation, BP was normalized with 5 mg/day amlodipine and psychiatric symptoms suddenly disappeared.
CONCLUSIONS: Psychopathological symptoms are rare at the onset of hyperaldosteronism, and their aetiology is not well defined. A proper diagnostic and therapeutic process is mandatory in order to get the recommended therapeutic targets in short-midterm improving long-term prognosis. We also suggest not considering depressed or treat with antidepressant agents a young hypertensive subject with uncontrolled hypertension despite multiple anti-hypertensive medications without having ruled out a secondary form of hypertension.

Entities:  

Keywords:  Anxiety; Depression; Pseudo-resistant hypertension; Renin-angiotensin system

Mesh:

Substances:

Year:  2016        PMID: 26729327     DOI: 10.1007/s40292-015-0128-x

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  39 in total

1.  Altered expression of renal NHE3, TSC, BSC-1, and ENaC subunits in potassium-depleted rats.

Authors:  Marie-Louise Elkjaer; Tae-Hwan Kwon; Weidong Wang; Jakob Nielsen; Mark A Knepper; Jørgen Frøkiaer; Søren Nielsen
Journal:  Am J Physiol Renal Physiol       Date:  2002-07-30

Review 2.  Is renal artery stenting the correct treatment of renal artery stenosis? The case for renal artery stenting for treatment of renal artery stenosis.

Authors:  Christopher J Cooper; Timothy P Murphy
Journal:  Circulation       Date:  2007-01-16       Impact factor: 29.690

3.  ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC).

Authors:  Michal Tendera; Victor Aboyans; Marie-Louise Bartelink; Iris Baumgartner; Denis Clément; Jean-Philippe Collet; Alberto Cremonesi; Marco De Carlo; Raimund Erbel; F Gerry R Fowkes; Magda Heras; Serge Kownator; Erich Minar; Jan Ostergren; Don Poldermans; Vincent Riambau; Marco Roffi; Joachim Röther; Horst Sievert; Marc van Sambeek; Thomas Zeller
Journal:  Eur Heart J       Date:  2011-08-26       Impact factor: 29.983

Review 4.  Arterial hypertension and thyroid disorders: what is important to know in clinical practice?

Authors:  A Mazza; G Beltramello; M Armigliato; D Montemurro; S Zorzan; M Zuin; L Rampin; M C Marzola; G Grassetto; A Al-Nahhas; D Rubello
Journal:  Ann Endocrinol (Paris)       Date:  2011-07-21       Impact factor: 2.478

5.  Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism.

Authors:  Norlela Sukor; Cynthia Kogovsek; Richard D Gordon; Dianne Robson; Michael Stowasser
Journal:  J Clin Endocrinol Metab       Date:  2010-01-20       Impact factor: 5.958

Review 6.  Mental depression and cardiovascular disease: a multifaceted, bidirectional association.

Authors:  Giuseppe Lippi; Martina Montagnana; Emmanuel J Favaloro; Massimo Franchini
Journal:  Semin Thromb Hemost       Date:  2009-05-18       Impact factor: 4.180

7.  The World Health Organization and the contested beginnings of psychiatric epidemiology as an international discipline: one rope, many strands.

Authors:  Anne M Lovell
Journal:  Int J Epidemiol       Date:  2014-07-16       Impact factor: 7.196

Review 8.  Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features.

Authors:  Alberto Mazza; Michela Armigliato; Maria Cristina Marzola; Laura Schiavon; Domenico Montemurro; Giorgio Vescovo; Marco Zuin; Sotirios Chondrogiannis; Roberta Ravenni; Giuseppe Opocher; Patrick M Colletti; Domenico Rubello
Journal:  Endocrine       Date:  2013-07-02       Impact factor: 3.633

9.  Diagnosis of primary aldosteronism in a patient with an incidentally found adrenal mass.

Authors:  Nicholas A Tritos
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-07

10.  Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.

Authors:  David Brent; Graham Emslie; Greg Clarke; Karen Dineen Wagner; Joan Rosenbaum Asarnow; Marty Keller; Benedetto Vitiello; Louise Ritz; Satish Iyengar; Kaleab Abebe; Boris Birmaher; Neal Ryan; Betsy Kennard; Carroll Hughes; Lynn DeBar; James McCracken; Michael Strober; Robert Suddath; Anthony Spirito; Henrietta Leonard; Nadine Melhem; Giovanna Porta; Matthew Onorato; Jamie Zelazny
Journal:  JAMA       Date:  2008-02-27       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.